The United States Patent Trial and Appeal Board has handed a win to Chinese-American synthetic biologist Feng Zhang (張鋒) and his team from the Massachusetts Institute of Technology (MIT) in a dispute over patents of the gene editing technology known as CRISPR.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Cross-Strait
KMT chair candidates willing to meet with Chinese leader for peace
10/11/2025 09:54 PM - Sports
Chen Chih-chieh wins men's fencing title at Singapore tourney
10/11/2025 08:53 PM - Business
85°C café to scale back China operations, expand in U.S.
10/11/2025 07:36 PM - Cross-Strait
Taiwan rebuts China's criticism of President Lai's National Day address
10/11/2025 06:58 PM - Business
EVA Air revenue falls in September, Starlux, Tigerair Taiwan report growth
10/11/2025 06:10 PM